Novo Nordisk A/S - share repurchase programme
04 September 2023 - 10:11PM
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark,
4 September
2023 – On 10 August 2023, Novo
Nordisk initiated a share repurchase programme in accordance with
Article 5 of Regulation No 596/2014 of the European Parliament and
Council of 16 April 2014 (MAR) and the Commission Delegated
Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour
Rules"). This programme is part of the overall share repurchase
programme of up to DKK 30 billion to be executed during a 12-month
period beginning 1 February 2023.
Under the programme initiated 10 August 2023, Novo Nordisk will
repurchase B shares for an amount up to DKK 5.7 billion in the
period from 10 August 2023 to 31 October 2023.
Since the announcement 28 August, the following transactions
have been made:
|
|
Number of B shares |
Average purchase price |
Transaction value,
DKK |
|
Accumulated, last announcement |
910,453 |
|
1,151,502,648 |
| 28 August
2023 |
77,000 |
1,286.89 |
99,090,600 |
| 29 August
2023 |
77,000 |
1,290.13 |
99,340,098 |
| 30 August
2023 |
77,000 |
1,292.91 |
99,554,369 |
| 31 August
2023 |
77,000 |
1,285.49 |
98,982,539 |
| 1 September
2023 |
72,128 |
1,285.17 |
92,696,975 |
|
Accumulated under the programme |
1,290,581 |
|
1,641,167,229 |
The details for each transaction made under the share repurchase
programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of
17,538,693 B shares of DKK0.20 as treasury shares, corresponding to
0.8% of the share capital. The total amount of A and B shares in
the company is 2,255,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to
DKK 30 billion during a 12-month period beginning 1 February 2023.
As of 1 September 2023, Novo Nordisk has since 1 February 2023
repurchased a total of 15,509,162 B shares at an average share
price of DKK 1,091.64 per B share equal to a transaction value of
DKK 16,930,397,814.
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat serious chronic diseases, built upon our heritage in
diabetes. We do so by pioneering scientific breakthroughs,
expanding access to our medicines, and working to prevent and
ultimately cure disease. Novo Nordisk employs about 59,000 people
in 80 countries and markets its products in around 170 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more
information, visit novonordisk.com, Facebook, Instagram, X,
LinkedIn and YouTube.
Contact for further information
|
Media: |
|
| Ambre
James-Brown +45 3079 9289abmo@novonordisk.com |
Natalia
Salomao Abrahao (US)+1 848 304
1027niaa@novonordisk.com |
|
Investors: |
|
|
Daniel Muusmann
Bohsen+45 3075 2175 dabo@novonordisk.com |
Jacob
Martin Wiborg Rode+45 3075 5956jrde@novonordisk.com |
| David
Heiberg Landsted +45 3077 6915 dhel@novonordisk.com |
Mark
Joseph Root (US) +1 848 213 3219mjhr@novonordisk.com |
Company announcement No 57 / 2023
- CA230904-Share-repurchase
- CA230904-transaction details
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Oct 2024 to Nov 2024
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Nov 2023 to Nov 2024
